Filtered By:
Source: Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
This page shows you your search results in order of date. This is page number 2.
Order by Relevance | Date
Total 68 results found since Jan 2013.
Renin ‐angiotensin‐aldosterone System Inhibitors and Major Cardiovascular Events and Acute Kidney Injury in Patients with Coronary Artery Disease
ConclusionsThis study supports the continued use of RAASIs in patients with CAD, although the benefit appears smaller in magnitude than observed in prior trials. High-risk patients, particularly those with prior MI, appear to benefit the most from RAASIs.
Source: Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy - September 8, 2021 Category: Drugs & Pharmacology Authors: Maneesh Sud,
Dennis T. Ko,
Alice Chong,
Maria Koh,
Paymon Azizi,
Peter C. Austin,
Therese Stukel,
Cynthia A. Jackevicius Tags: ORIGINAL RESEARCH ARTICLE Source Type: research
Effects of aging on clinical outcomes in patients receiving genotype ‐guided P2Y12 inhibitor selection after percutaneous coronary intervention
ConclusionThis study suggests important clinical benefits ofCYP2C19 genotype-guided antiplatelet therapy after PCI in both younger and older patients.
Source: Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy - July 21, 2021 Category: Drugs & Pharmacology Authors: Brian Wood,
Craig R. Lee,
Ian R. Mulrenin,
Megan N. Gower,
Joseph S. Rossi,
Karen E. Weck,
George A. Stouffer Tags: TI on Advances in Cardiovascular Pharmacotherapy Source Type: research
Effects of Aging on Clinical Outcomes in Patients Receiving Genotype ‐Guided P2Y12 Inhibitor Selection after Percutaneous Coronary Intervention
ConclusionThis study suggests important clinical benefits ofCYP2C19 genotype-guided antiplatelet therapy after PCI in both younger and older patients.
Source: Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy - July 10, 2021 Category: Drugs & Pharmacology Authors: Brian Wood,
Craig R. Lee,
Ian R. Mulrenin,
Megan N. Gower,
Joseph S. Rossi,
Karen E. Weck,
George A. Stouffer Tags: ORIGINAL RESEARCH Source Type: research
TT genotype of the MMP ‐9‐1562C/T polymorphism may be a risk factor for thrombolytic therapy‐induced hemorrhagic complications after acute ischemic stroke
ConclusionTT genotype of theMMP-9-1562C/T polymorphism may be a risk factor for rtPA-induced hemorrhagic complications after AIS.
Source: Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy - May 28, 2021 Category: Drugs & Pharmacology Authors: Marija Dusanovic Pjevic,
Biljana Jekic,
Ljiljana Beslac Bumbasirevic,
Ljubica Vojvodic,
Tatjana Damnjanovic,
Milka Grk,
Nela Maksimovic,
Milica Pesic,
Milica Gulic,
Jelena Trickovic,
Katarina Kacar Tags: ORIGINAL RESEARCH ARTICLE Source Type: research
2,5TT genotype of the MMP ‐9‐1562C/T polymorphism may be a risk factor for thrombolytic therapy‐induced hemorrhagic complications after acute ischemic stroke
ConclusionTT genotype of theMMP ‐9‐1562C/T polymorphism may be a risk factor for rtPA‐induced hemorrhagic complications after AIS.
Source: Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy - May 4, 2021 Category: Drugs & Pharmacology Authors: Marija Dusanovic Pjevic,
Biljana Jekic,
Ljiljana Beslac Bumbasirevic,
Ljubica Vojvodic,
Tatjana Damnjanovic,
Milka Grk,
Nela Maksimovic,
Milica Pesic,
Milica Gulic,
Jelena Trickovic,
Katarina Kacar Tags: ORIGINAL RESEARCH ARTICLE Source Type: research
Comparative Effectiveness and Safety of Prasugrel versus Ticagrelor following Percutaneous Coronary Intervention: An Observational Study
ConclusionWhen compared with ticagrelor, prasugrel use following PCI for ACS was associated with a lower risk of death, MI, or stroke, as well as a reduced risk of major bleeding.
Source: Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy - May 1, 2021 Category: Drugs & Pharmacology Authors: Nicholas Belviso,
Herbert D. Aronow,
Richard Wyss,
Marilyn Barbour,
Yichi Zhang,
Xuerong Wen,
Stephen Kogut Tags: ORIGINAL RESEARCH ARTICLE Source Type: research
U.S. trends in prescription nonsteroidal anti ‐inflammatory drug use among patients with cardiovascular disease, 1988–2016
ConclusionsPrescription NSAID use among patients with CVD appears to have declined from 1988 to 2016, primarily due to reduced COX ‐2‐selective inhibitor use. Nonetheless, the prevalence of prescription NSAIDs has persisted among a subset of high‐risk CVD populations.
Source: Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy - March 9, 2021 Category: Drugs & Pharmacology Authors: Andrew Y. Hwang,
Steven M. Smith Tags: ORIGINAL RESEARCH ARTICLE Source Type: research
Comparative effectiveness and safety of high ‐dose rivaroxaban and apixaban for atrial fibrillation: A propensity score‐matched cohort study
ConclusionIn this study, composite effectiveness and safety varied between rivaroxaban and apixaban. High ‐dose apixaban was observed to have a better effectiveness and safety.
Source: Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy - February 27, 2021 Category: Drugs & Pharmacology Authors: Sylvie Perreault,
Alice Dragomir,
Robert C ôté,
Aurélie Lenglet,
Brian White‐Guay,
Simon Denus,
Mireille E. Schnitzer,
Marie‐Pierre Dubé,
James M. Brophy,
Marc Dorais,
Jean‐Claude Tardif Tags: ORIGINAL RESEARCH ARTICLE Source Type: research
Comparative Effectiveness and Safety of High ‐Dose Rivaroxaban and Apixaban for Atrial Fibrillation: A Propensity Score‐Matched Cohort Study
ConclusionIn this study, composite effectiveness and safety varied between rivaroxaban and apixaban. High ‐dose apixaban was observed to have better effectiveness and safety in patients with AF.
Source: Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy - February 5, 2021 Category: Drugs & Pharmacology Authors: Sylvie Perreault,
Alice Dragomir,
Robert C ôté,
Aurélie Lenglet,
Brian White‐Guay,
Simon de Denus,
Mireille E Schnitzer,
Marie‐Pierre Dubé,
James M Brophy,
Marc Dorais,
Jean‐Claude Tardif Tags: ORIGINAL RESEARCH ARTICLE Source Type: research
U.S. trends in prescription nonsteroidal anti ‐inflammatory drug use among patients with cardiovascular disease, 1988–2016
ConclusionsPrescription NSAID use among patients with CVD appears to have declined from 1988 to 2016, primarily due to reduced COX ‐2‐selective inhibitor use. Nonetheless, the prevalence of prescription NSAIDs has persisted among a subset of high‐risk CVD populations.
Source: Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy - January 9, 2021 Category: Drugs & Pharmacology Authors: Andrew Y. Hwang,
Steven M. Smith Tags: ORIGINAL RESEARCH ARTICLE Source Type: research
